PHP169 - MCDA EVIDEM REFERENCE VALUE FRAMEWORK FOR DRUG EVALUATION AND DECISION MAKING IN SPAIN

Abstract

Listen

Translate article

To obtain an MCDA reference value framework to use the EVIDEM framework in drug evaluation and decision making in Spain. MCDA training sessions involving evaluators and decision-makers from 2 national and 5 regional Spanish healthcare evaluation bodies were performed using the EVIDEM framework. In each session, quantitative criteria were presented and weighted using a non-hierarchical 5-point weighting scale (5 being the highest importance). Mean score was calculated for each criterion and compared between national and regional evaluators and decision-makers applying the t-test, being the null hypothesis that national and regional weight scores would be the same. Criteria were weighted by a total of 98 Spanish evaluators and decision makers (25 at national level and 73 at regional level). The most important criteria of the reference value framework were “disease severity”, “comparative efficacy”, “quality of evidence” and “comparative safety”. The less important criteria were “size of affected population, “expert consensus/clinical practice guidelines” and “comparative non-medical costs”. There were no statistical differences in the assigned weight scores between national and regional evaluators and decision makers except for “comparative patient-reported outcomes (PROs)”, where regional evaluators and decision-makers scored +0.6 out of 5 (p<0,01). An MCDA EVIDEM reference value framework for drug evaluation and decision making in Spain has been obtained, which could be used as reference values when applying the EVIDEM framework for drug evaluation in Spain. Evaluators and decision makers considered the EVIDEM criteria relevant and applicable for health technology value assessment. No differences between the relative importance given to EVIDEM criteria by national and regional evaluators and decision makers in Spain were found except for “comparative PROs”, which is higher valued in regional healthcare evaluations.